Charles River Laboratories International, and Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.
Supporting the first gene therapy platform targeting renal diseases, that affect approximately 840 million people, around 10 percent of the global population, the program leverages Charles River’s established plasmid platform, eXpDNA, and decades of experience at the company’s plasmid DNA manufacturing center of excellence.
